Q-omics provides the consensus-scored TM4SF19-TCTEX1D2 profile across patient tissues and cancer cell-line models. TM4SF19-TCTEX1D2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TM4SF19-TCTEX1D2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, TM4SF19-TCTEX1D2 RNA expression shows 10,206 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, HNSC, and ESCA as cancer lineages where TM4SF19-TCTEX1D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TM4SF19-TCTEX1D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TM4SF19-TCTEX1D2 survival associations across molecular data types. TM4SF19-TCTEX1D2 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TM4SF19-TCTEX1D2 RNA expression–survival associations across cancer types. High TM4SF19-TCTEX1D2 expression shows unfavorable associations in KIRC, ACC, LIHC, UVM and PCPG, but favorable associations in PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TM4SF19-TCTEX1D2 RNA expression.
This table summarizes TM4SF19-TCTEX1D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for TM4SF19-TCTEX1D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TM4SF19-TCTEX1D2 shows lower tumor expression in KICH and higher tumor expression in HNSC, LUSC, COAD, KIRC and BLCA. The HNSC box plot shows higher TM4SF19-TCTEX1D2 RNA expression in tumor versus normal tissue (log2 FC = +0.618, t-test p < 0.001).
This table shows molecular features associated with TM4SF19-TCTEX1D2 in patient tissues and cancer cell lines. In patient samples, TM4SF19-TCTEX1D2 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, TM4SF19-TCTEX1D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS.
